$55m financing round for NVision

With a new $55m financing round and Abbott joining as lead investor, Ulm-based quantum technology company NVision Imaging Technologies GmbH is significantly broadening its ambitions beyond its existing work in quantum sensing. Going forward, the company also aims to make quantum computing usable for drug development, creating an integrated approach that brings drug design and biological validation closer together.

Metabolism on screen

At the centre of this effort is POLARIS, the MRI platform the company has already developed, which uses quantum technology methods to visualise metabolic processes in real time. The system amplifies MRI signals from sugar-based contrast agents by several orders of magnitude, enabling insights into disease processes much earlier than conventional imaging methods. Instead of waiting months for structural changes to appear, researchers could detect treatment effects within hours or days.

According to the company, POLARIS is now being installed at leading cancer centres, including Memorial Sloan Kettering Cancer Center, the University of Cambridge and the Technical University of Munich. By the end of the year, around 20 systems are expected to be in use across Europe, the US and Asia.

Building on the molecular quantum technology developed for this platform, NVision now wants to take the next step. During its work on the MRI platform, the company says it created a new class of organic molecule-based qubits that can now be used for photonic quantum computers. The new platform is called “Photonic Integrated Quantum Circuits” — PIQC, pronounced “Pixie”.

Digital medicine: knowledge will explode

“I see a future in which quantum computers generate an explosive increase in new drug hypotheses for diseases that are extraordinarily difficult to treat today,” said co-founder and CEO Sella Brosh. The decisive factor, he added, will be the ability to test those insights biologically and quickly. That is precisely where POLARIS is intended to close the gap between computer-aided design and real biology.

In doing so, NVision is positioning itself at an interface that is currently regarded worldwide as one of the most ambitious long-term fields in the life sciences: the combination of quantum computing and drug development. While major technology companies and pharmaceutical groups have been working on quantum-enabled simulation methods for years, there are still only a few practical applications with a direct link to clinical research.

The new financing round underlines the growing interest of institutional and strategic investors in this approach. In addition to Abbott, participants include CDP Venture Capital, Playground Global, Matterwave Ventures and Entrée Capital. The round also includes a $17m venture loan from the European Investment Bank. According to NVision, this brings the company’s total funding to around $120m.

For NVision, Abbott’s participation marks the arrival of a strategic partner in diagnostics. The medical technology group is particularly interested in evaluating the potential of quantum technology methods for diagnosis and clinical decision-making.

“What particularly impresses us about NVision is the company’s ability to translate complex quantum science into scalable systems for practical use,” said Peter Karabatsos of Abbott. While the field remains at an early stage, he added, it could open up new ways of understanding biological systems.

Investors see an early opportunity

Investors also see the combination of quantum sensing and quantum computing as a potential new platform technology for biomedical research. Peter Barrett, General Partner at Playground Global, described it as a new category of “quantum technologies for medicine” that could encompass both drug design and the validation of new therapies.

Despite the technological vision, practical implementation remains an enormous challenge. Quantum computing is still considered an experimental field, with scalability, fault tolerance and industrial usability remaining unresolved problems. NVision is therefore deliberately focusing on concrete healthcare applications — an area where the benefits of quantum technology methods could become visible comparatively early.

For Europe’s technology ecosystem, the move is nevertheless notable. While many quantum computing initiatives have so far been dominated by US technology companies, NVision represents a European approach that connects quantum physics directly with clinical research and pharmaceutical development.